BiotechTube

Placebo + Alirocumab

Phase 3Completed
0 watching 0 views this week📈 Rising
76
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Heterozygous Familial Hypercholesterolemia

Conditions

Heterozygous Familial Hypercholesterolemia

Trial Timeline

Mar 31, 2015 → Apr 30, 2016

NCT ID
NCT02326220

About Placebo + Alirocumab

Placebo + Alirocumab is a phase 3 stage product being developed by Sanofi for Heterozygous Familial Hypercholesterolemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02326220. Target conditions include Heterozygous Familial Hypercholesterolemia.

Hype Score Breakdown

Clinical
27
Activity
18
Company
9
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02326220Phase 3Completed

Competing Products

18 competing products in Heterozygous Familial Hypercholesterolemia

See all competitors
ProductCompanyStageHype Score
AZD0780 + PlaceboAstraZenecaPhase 3
77
Anacetrapib + Placebo for anacetrapibMerckPhase 3
77
Enlicitide Decanoate + PlaceboMerckPhase 2/3
65
InclisiranNovartisPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
FluvastatinNovartisPhase 3
77
Inclisiran + PlaceboNovartisPhase 3
77
Evolocumab + PlaceboAmgenPhase 3
76
Bococizumab (PF-04950615;RN316)PfizerPhase 3
76
Atorvastatin + AtorvastatinPfizerPhase 1
32
IBI306 + placeboInnovent BiologicsPhase 3
76
Lumacaftor Plus Ivacaftor Combination + IvacaftorVertex PharmaceuticalsPhase 3
76
LMT (atorvastatin, simvastatin, or rosuvastatin) + alirocumab + PlaceboSanofiPhase 3
76
PraluentSanofiApproved
84
AK102 + Placebo + Statins and/or EzetimibeAkesoPhase 2
51
lerodalcibepMedpacePhase 3
74
mipomersen sodium + placeboIonis PharmaceuticalsPhase 3
74
MGL-3196 (resmetirom) + PlaceboMadrigal PharmaceuticalsPhase 2
49

Other Products from Sanofi

Adacel®Approved
84
LACTIC ACID(ND)Approved
84
DupilumabApproved
84
glatiramer acetateApproved
84
INSULIN GLULISINE + INSULIN GLARGINEApproved
84